drugset / Trial / NCT01541943

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

NCT01541943

Phase 3 Completed 356 enrolled HanAll BioPharma Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia

Timeline

Start
2012-03
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule Oral
Subject HL040XC Unknown Oral
Comparator Losartan Other / unclassified Oral